|
May 14
|
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
|
|
Apr 29
|
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
|
|
Mar 19
|
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
|
|
Mar 19
|
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
|
|
Jan 9
|
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
|
|
Jan 2
|
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
|
|
Dec 29
|
11 Best Psychedelic Stocks to Buy in 2024
|
|
Dec 22
|
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
|
|
Dec 20
|
11 Most Promising Psychedelic Stocks According to Hedge Funds
|
|
Dec 4
|
Insider Spends US$100k Buying More Shares In Seelos Therapeutics
|
|
Dec 2
|
Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)
|
|
Dec 1
|
Seelos Therapeutics Announces Closing of Public Offering
|
|
Aug 14
|
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
|
|
Aug 13
|
Seelos Therapeutics' (NASDAQ:SEEL) investors will be pleased with their decent 52% return over the last year
|